| What is dysplasia? |
|
Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointestinal Endoscopy 1999; 50(1):23-6. |
|
Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. Journal of the National Cancer Institute 2000; 92(16):1316-21. |
|
Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120(7):1630-9. |
|
Dar MS, Goldblum JR, Rice TW, and Falk GW, Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut, 2003. 52(4): p. 486-9. |
|
Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96(5 Pt 1):1249-56. |
|
Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas G. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994; 107(4):1012-8. |
|
Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. American Journal Of Gastroenterology 1998; 93(4):536-41. |
|
Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clinic Proceedings 2001; 76(4):438-46. |
|
Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105(1):40-50. |
|
Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32(12):1441-6. |
|
Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Zahurak ML, Hart J. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Human Pathology 2001; 32(4):379-88. |
|
Polkowski W, Baak JP, van Lanschot JJ, Meijer GA, Schuurmans LT, Ten Kate FJ, Obertop H, Offerhaus GJ. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol 1998; 184(2):161-8. |
|
Polkowski W, van Lanschot JJ, Ten Kate FJ, Baak JP, Tytgat GN, Obertop H, Voorn WJ, Offerhaus GJ. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 1995; 4(3):163-71. |
|
Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102(4 Pt 1):1212-9. |
|
Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Human Pathology 1988; 19(2):166-78. |
|
Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. American Journal of Gastroenterology 2000; 95(7):1669-76. |
|
Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. The American Journal of Gastroenterology 2001; 96(10):2839-48. |
|
Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988; 75(8):760-3. |
|
Sagan C, Flejou JF, Diebold MD, Potet F, Le Bodic MF. [Reproducibility of histological criteria of dysplasia in Barrett mucosa]. Gastroenterol Clin Biol 1994; 18(1):D31-4. |
|
Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93(7):1028-32. |
|
Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. The American Journal of Gastroenterology 2002; 97(8):1888-95. |
|
Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O_Connell S, Seidel UJ, Sonnenberg A. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120(7):1607-19. |
|
Teodori L, Gohde W, Persiani M, Ferrario F, Tirindelli Danesi D, Scarpignato C, Di Tondo U, Alo P, Capurso L. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998; 34(6):257-63. |
|
van Lieshout EM, Jansen JB, Peters WH. Biomarkers in Barrett's esophagus. Int J Oncol 1998; 13(4):855-64. |
|
van Sandick JW, Baak JP, van Lanschot JJ, Polkowski W, ten Kate FJ, Obertop H, Offerhaus GJ. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J Pathol 2000; 190(2):177-183. |
|
Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. The American Journal of Gastroenterology 2001; 96(5):1355-62. |
|
Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Research 2001; 61(22):8284-9. |
|
Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993; 105(6):1637-42. |
|
